Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency

Papers of special note have been highlighted as: • of interest

References

• 1. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem. Rev. 116(4), 2602–2663 (2016). • Review for the chemical and biomedical aspects of polymeric nanoparticles.
  Medline CASGoogle Scholar
• 2. Fang JY, Al-Suwayeh SA. Nanoparticles as delivery carriers for anticancer prodrugs. Expert Opin. Drug Deliv. 9(6), 657–669 (2012).
  Medline CASGoogle Scholar
• 3. Wermuth CG, Ganellin CR, Lindberg P, Mitscher LA. Glossary of terms used in medicinal chemistry. Pure Appl. Chem. 70(5), 1129–1143 (1998).
  CASGoogle Scholar
• 4. Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Discov. doi:10.1038/nrd.2018.46 (2018) (Epub ahead of print). • Review for the rationale of prodrug design.
  MedlineGoogle Scholar
• 5. Wang Y, Sun S, Zhang Z, Shi D. Nanomaterials for cancer precision medicine. Adv. Mater. 30(17), e1705660 (2018).
  MedlineGoogle Scholar
• 6. Vert M, Doi Y, Hellwich KH et al. Terminology for biorelated polymers and applications (IUPAC recommendations 2012). Pure Appl. Chem. 84(2), 377–410 (2012).
  CASGoogle Scholar
• 7. Chou YP, Lin YK, Chen CH, Fang JY. Recent advances in polymeric nanosystems for treating cutaneous melanoma and its metastasis. Curr. Pharm. Design 23(35), 5301–5314 (2017).
  Medline CASGoogle Scholar
• 8. Huttunen KM, Raunio H, Rautio J. Prodrugs—from serendipity to rational design. Pharmacol. Rev. 63(3), 750–771 (2011).
  Medline CASGoogle Scholar
• 9. Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem. Rev. 116(5), 3436–3486 (2016).
  Medline CASGoogle Scholar
• 10. Fumagalli G, Marucci C, Christodoulou MS, Stella B, Dosio F, Passarella D. Self-assembly drug conjugates for anticancer treatment. Drug Discov. Today 21(8), 1321–1329 (2016).
  Medline CASGoogle Scholar
• 11. Giang I, Boland EL, Poon GM. Prodrug applications for targeted cancer therapy. AAPS J. 16(5), 899–913 (2014).
  Medline CASGoogle Scholar
• 12. Hsieh PW, Hung CF, Fang JY. Current prodrug design for drug discovery. Curr. Pharm. Design 15(19), 2236–2250 (2009).
  Medline CASGoogle Scholar
• 13. Jornada DH, dos Santos Fernandes GF, Chiba DE, de Melo TR, dos Santos JL, Chung MC. The prodrug approach: a successful tool for improving drug solubility. Molecules 21(1), 42 (2015).
  MedlineGoogle Scholar
• 14. Cacciatore I, Ciulla M, Marinelli L, Eusepi P, Di Stefano A. Advances in prodrug design for Parkinson's disease. Expert Opin. Drug Discov. 13(4), 295–305 (2018).
  Medline CASGoogle Scholar
• 15. Cao H, Wang K, Ye YL, Shen JH. Orally administrated small molecule drugs with intestine targeted profile: recent development and prospects. Curr. Med. Chem. 24(35), 3921–3937 (2017).
  Medline CASGoogle Scholar
• 16. Bae KH, Chung HJ, Park TG. Nanomaterials for cancer therapy and imaging. Mol. Cells 31(4), 295–302 (2011). • Nanoparticle approach for cancer therapy and diagnosis.
  Medline CASGoogle Scholar
• 17. Ladj R, Bitar A, Eissa MM et al. Polymer encapsulation of inorganic nanoparticles for biomedical applications. Int. J. Pharm. 458(1), 230–241 (2013).
  Medline CASGoogle Scholar
• 18. Liu FC, Yu HP, Lin CY, Elzoghby AO, Hwang TL, Fang JY. Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge. J. Nanobiotechnol. 16(1), 35 (2018).
  MedlineGoogle Scholar
• 19. Bodo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm. Res. 33(10), 2373–2387 (2016). • The introduction of US FDA-approved nanomedicines.
  MedlineGoogle Scholar
• 20. Mura S, Bui DT, Couvreur P, Nicolas J. Lipid prodrug nanocarriers in cancer therapy. J. Control. Rel. 208, 25–41 (2015).
  Medline CASGoogle Scholar
• 21. Palange AL, Di Mascolo D, Carallo C, Gnasso A, Decuzzi P. Lipid-polymer nanoparticles encapsulating curcumin for modulating the vascular deposition of breast cancer cells. Nanomed. Nanotechnol. Biol. Med. 10(5), 991–1002 (2014).
  Medline CASGoogle Scholar
• 22. Boal AK, Ilhan F, DeRouchey JE, Thurn-Albrecht T, Russell TP, Rotello VM. Self-assembly of nanoparticles into structured spherical and network aggregates. Nature 404(6779), 746–748 (2000).
  Medline CASGoogle Scholar
• 23. Zhang WJ, Hong CY, Pan CY. Polymerization-induced self-assembly of functionalized block copolymer nanoparticles and their application in drug delivery. Macromol. Rapid Commun. 39, e1800279 (2018).
  Google Scholar
• 24. Liechty WB, Kryscio DR, Slaughter BV, Peppas NA. Polymers for drug delivery systems. Annu. Rev. Chem. Biomol. Eng. 1, 149–173 (2010).
  Medline CASGoogle Scholar
• 25. Chou YP, Lin YK, Chen CH, Fang JY. Recent advances in polymeric nanosystems for treating cutaneous melanoma and its metastasis. Curr. Pharm. Design 23(35), 5301–5314 (2017).
  Medline CASGoogle Scholar
• 26. Albisa A, Espanol L, Prieto M, Sebastian V. Polymeric nanomaterials as nanomembrane entities for biomolecule and drug delivery. Curr. Pharm. Design 23(2), 263–280 (2017).
  Medline CASGoogle Scholar
• 27. Daneluti ALM, Neto FM, Velasco MVR, Baby AR, Matos JDR. Evaluation and characterization of the encapsulation/entrapping process of octyl methoxycinnamate in ordered mesoporous silica type SBA-15. J. Therm. Anal. Calorim. 131(1), 789–798 (2018).
  CASGoogle Scholar
• 28. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J. Mater. Chem. 21(16), 5845 (2011).
  CASGoogle Scholar
• 29. Lin MH, Lin CF, Yang SC, Hung CF, Fang JY. The interplay between nanoparticles and neutrophils. J. Biomed. Nanotechnol. 14(1), 66–85 (2018).
  Medline CASGoogle Scholar
• 30. Mody VV, Siwale R, Singh A, Mody HR. Introduction to metallic nanoparticles. J. Pharm. Bioallied. Sci. 2(4), 282–289 (2010).
  Medline CASGoogle Scholar
• 31. Del Pozo-Rodríguez A, Solinís MÁ, Rodríguez-Gascón A. Applications of lipid nanoparticles in gene therapy. Eur. J. Pharm. Biopharm. 109, 184–193 (2016).
  MedlineGoogle Scholar
• 32. Singh Y, Meher JG, Raval K et al. Nanoemulsion: concepts, development and applications in drug delivery. J. Control. Rel. 252, 28–49 (2017).
  Medline CASGoogle Scholar
• 33. Rostami E, Kashanian S, Azandaryani AH, Faramarzi H, Dolatabadi JE, Omidfar K. Drug targeting using solid lipid nanoparticles. Chem. Phys. Lipids 181, 56–61 (2014).
  Medline CASGoogle Scholar
• 34. Lin CH, Chen CH, Lin ZC, Fang JY. Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J. Food Drug Anal. 25(2), 219–234 (2017).
  Medline CASGoogle Scholar
• 35. Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomed. Nanotechnol. Biol. Med. 12(1), 143–161 (2016).
  Medline CASGoogle Scholar
• 36. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13(5), 273–290 (2016).
  Medline CASGoogle Scholar
• 37. Vargas JR, Stanzl EG, Teng NN, Wender PA. Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance. Mol. Pharm. 11(8), 2553–2565 (2014).
  Medline CASGoogle Scholar
• 38. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 10(9), 3223–3230 (2010). • Review for nanoparticle application on drug delivery and targeting.
  Medline CASGoogle Scholar
• 39. Clancy P. Nanoparticles: self-assembly finds its own limits. Nat. Nanotechnol. 6(9), 540–541 (2011).
  Medline CASGoogle Scholar
• 40. Duhem N, Danhier F, Pourcelle V et al. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity. Bioconjug. Chem. 25(1), 72–81 (2014).
  Medline CASGoogle Scholar
• 41. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33(9), 941–951 (2015). • The strategy of using nanoparticles for facile biomembrane permeation.
  Medline CASGoogle Scholar
• 42. Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug. Chem. 27(10), 2225–2238 (2016).
  Medline CASGoogle Scholar
• 43. Theile D. Under-reported aspects of platinum drug pharmacology. Molecules 22(3), E382 (2017).
  MedlineGoogle Scholar
• 44. Köberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim. Biophys. Acta 1806(2), 172–182 (2010).
  MedlineGoogle Scholar
• 45. Shi Y, Liu SA, Kerwood DJ, Goodisman J, Dabrowiak JC. Pt(IV) complexes as prodrugs for cisplatin. J. Inorg. Biochem. 107(1), 6–14 (2012).
  Medline CASGoogle Scholar
• 46. Song H, Kang X, Sun J et al. Nanoparticle delivery of sterically hindered platinum(IV) prodrugs shows 100-times higher potency than that of cisplatin upon light activation. Chem. Commun. 52(11), 2281–2283 (2016).
  Medline CASGoogle Scholar
• 47. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int. J. Cancer 119(2), 243–250 (2006).
  Medline CASGoogle Scholar
• 48. Sun Y, Shi T, Zhou L, Zhou Y, Sun B, Liu X. Folate-decorated and NIR-activated nanoparticles based on platinum(IV) prodrugs for targeted therapy of ovarian cancer. J. Microencapsul. 34(7), 675–686 (2017).
  Medline CASGoogle Scholar
• 49. Botella P, Rivero-Buceta E. Safe approaches for camptothecin delivery: structural analogues and nanomedicines. J. Control. Rel. 247, 28–54 (2017). • The approach of camptothecin prodrugs for increased bioavailability.
  Medline CASGoogle Scholar
• 50. Liu J, Liu W, Weitzhandler I et al. Ring-opening polymerization of prodrugs: a versatile approach to prepare well-defined drug-loaded nanoparticles. Angew. Chem. Int. Ed. Engl. 54(3), 1002–1006 (2015).
  Medline CASGoogle Scholar
• 51. Kang Y, Ju X, Ding LS, Zhang S, Li BJ. Reactive oxygen species and glutathione dual redox-responsive supramolecular assemblies with controllable release capability. ACS Appl. Mater. Interfaces 9(5), 4475–4484 (2017).
  Medline CASGoogle Scholar
• 52. He W, Jiang Y, Li Q, Zhang D, Li Z, Luan Y. A versatile strategy to create an active tumor-targeted chemo-photothermal therapy nanoplatform: a case of an IR-780 derivative co-assembled with camptothecin prodrug. Acta Biomater. 84, 356–366 (2019).
  Medline CASGoogle Scholar
• 53. Yin W, Ke W, Chen W et al. Integrated block copolymer prodrug nanoparticles for combination of tumor oxidative stress amplification and ROS-responsive drug release. Biomaterials 195, 63–74 (2019).
  Medline CASGoogle Scholar
• 54. Zhang Y, Xiao C, Li M et al. Co-delivery of 10-hydroxycamptothecin with doxorubicin conjugated prodrugs for enhanced anticancer efficacy. Macromol. Biosci. 13(5), 584–594 (2013).
  Medline CASGoogle Scholar
• 55. Li D, Ding J, Zhuang X, Chen L, Chen X. Drug binding rate regulates the properties of polysaccharide prodrugs. J. Mater. Chem. B 4(30), 5167 (2016).
  Medline CASGoogle Scholar
• 56. Wang Y, Liu D, Zheng Q et al. Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines. Nano Lett. 14(10), 5577–5583 (2014).
  Medline CASGoogle Scholar
• 57. Cheng R, Feng F, Meng F, Deng C, Feijen J, Zhong Z. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J. Control. Rel. 152(1), 2–12 (2011).
  Medline CASGoogle Scholar
• 58. Shim MK, Park J, Yoon HY et al. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy. J. Control. Rel. 294, 376–389 (2019).
  Medline CASGoogle Scholar
• 59. Xu C, He W, Lv Y, Qin C, Shen L, Yin L. Self-assembled nanoparticles from hyaluronic acid-paclitaxel prodrugs for direct cytosolic delivery and enhanced antitumor activity. Int. J. Pharm. 493(1–2), 172–181 (2015).
  Medline CASGoogle Scholar
• 60. Zhong Y, Zhang J, Cheng R et al. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. J. Control. Rel. 205, 144–154 (2015).
  Medline CASGoogle Scholar
• 61. Sun B, Luo C, Cui W, Sun J, He Z. Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy. J. Control. Rel. 264, 145–159 (2017).
  Medline CASGoogle Scholar
• 62. Zhong T, Yao X, Zhang S et al. A self-assembling nanomedicine of conjugated linoleic acid-paclitaxel conjugate (CLA-PTX) with higher drug loading and carrier-free characteristic. Sci. Rep. 6, 36614 (2016).
  Medline CASGoogle Scholar
• 63. Luo C, Sun J, Liu D et al. Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy. Nano Lett. 16(9), 5401–5408 (2016).
  Medline CASGoogle Scholar
• 64. Luo C, Sun J, Sun B et al. Facile fabrication of tumor redox-sensitive nanoassemblies of small-molecule oleate prodrug as potent chemotherapeutic nanomedicine. Small 12(46), 6353–6362 (2016).
  Medline CASGoogle Scholar
• 65. Huang D, Zhuang Y, Shen H, Yang F, Wang X, Wu D. Acetal-linked PEGylated paclitaxel prodrugs forming free-paclitaxel-loaded pH-responsive micelles with high drug loading capacity and improved drug delivery. Mater. Sci. Eng. C Mater. Biol. Appl. 82, 60–68 (2018).
  Medline CASGoogle Scholar
• 66. Ke W, Yin W, Zha Z et al. A robust strategy for preparation of sequential stimuli-responsive block copolymer prodrugs via thiolactone chemistry to overcome multiple anticancer drug delivery barriers. Biomaterials 154, 261–274 (2018).
  Medline CASGoogle Scholar
• 67. Wang H, Chen J, Xu C et al. Cancer nanomedicines stabilized by π-π stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations. Theranostics 7(15), 3638–3652 (2017).
  Medline CASGoogle Scholar
• 68. Duan XC, Yao X, Zhang S et al. Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo. Int. J. Nanomed. 14, 195–204 (2018).
  Medline CASGoogle Scholar
• 69. Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed. Chromatogr. 24(1), 104–123 (2010).
  MedlineGoogle Scholar
• 70. Fujita K, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J. Gastroenterol. 21(43), 12234–12248 (2015).
  Medline CASGoogle Scholar
• 71. Makiyama A, Arimizu K, Hirano G et al. Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. Gastric Cancer 21(3), 464–472 (2018).
  Medline CASGoogle Scholar
• 72. Zhang C, Jin S, Xue X, Zhang T, Jiang Y, Wang PC, Liang XJ. Tunable self-assembly of Irinotecan-fatty acid prodrugs with increased cytotoxicity to cancer cells. J. Mater. Chem. B 4(19), 3286–3291 (2016).
  Medline CASGoogle Scholar
• 73. Zashikhina NN, Volokitina MV, Korzhikov-Vlakh VA et al. Self-assembled polypeptide nanoparticles for intracellular irinotecan delivery. Eur. J. Pharm. Sci. 109, 1–12 (2017).
  Medline CASGoogle Scholar
• 74. Wang H, Xie H, Wu J et al. Structure-based rational design of prodrugs to enable their combination with polymeric nanoparticle delivery platforms for enhanced antitumor efficacy. Angew. Chem. Int. Ed. Engl. 53(43), 11532–11537 (2014).
  Medline CASGoogle Scholar
• 75. Sauraj, Kumar V, Kumar B et al. Lipophilic 5-fluorouracil prodrug encapsulated xylan-stearic acid conjugates nanoparticles for colon cancer therapy. Int. J. Biol. Macromol. 128, 204–213 (2019).
  Medline CASGoogle Scholar
• 76. Johnstone TC, Lippard SJ. The effect of ligand lipophilicity on the nanoparticle encapsulation of Pt(IV) prodrugs. Inorg. Chem. 52(17), 9915–9920 (2013). • An example to load platinum prodrugs into nanoparticles.
  Medline CASGoogle Scholar
• 77. Margiotta N, Savino S, Denora N et al. Encapsulation of lipophilic kiteplatin Pt(IV) prodrugs in PLGA-PEG micelles. Dalton Trans. 45(33), 13070–13081 (2016).
  Medline CASGoogle Scholar
• 78. Shamsuddin S, Santillan CC, Stark JL, Whitmire KH, Siddik ZH, Khokhar AR. Synthesis, characterization, and antitumor activity of new platinum(IV) trans-carboxylate complexes: crystal structure of [Pt(cis-1,4-DACH)trans-(acetate)₂Cl₂]. J. Inorg. Biochem. 71(1–2), 29–35 (1998).
  Medline CASGoogle Scholar
• 79. Chen Q, Yang Y, Lin X et al. Platinum(IV) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance. Chem. Commun. 54(42), 5369–5372 (2018).
  Medline CASGoogle Scholar
• 80. Gao Y, Jiang M, Ma Y et al. Nanoparticle-mediated delivery of multinuclear platinum(IV) prodrugs with enhanced drug uptake and the activity of overcoming drug resistance. Anticancer Drugs 27(2), 77–83 (2016).
  Medline CASGoogle Scholar
• 81. Liu XQ, Picart C. Layer-by-layer assemblies for cancer treatment and diagnosis. Adv. Mater. 28(6), 1295–1301 (2016). • The introduction of layer-by-layer nanoparticles.
  Medline CASGoogle Scholar
• 82. Zhang R, Ru Y, Gao Y, Li J, Mao S. Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer. Drug Des. Devel. Ther. 11, 2631–2642 (2017).
  Medline CASGoogle Scholar
• 83. Ling X, Chen X, Riddell IA et al. Glutathione-scavenging poly(disulfide amide) nanoparticles for the effective delivery of Pt(IV) prodrugs and reversal of cisplatin resistance. Nano Lett. 18(7), 4618–4625 (2018).
  Medline CASGoogle Scholar
• 84. Huang M, Zhao K, Wang L et al. Dual stimuli-responsive polymer prodrugs quantitatively loaded by nanoparticles for enhanced cellular internalization and triggered drug release. ACS Appl. Mater. Interfaces 8(18), 11226–11236 (2016).
  Medline CASGoogle Scholar
• 85. Wohl AR, Michel AR, Kalscheuer S, Macosko CW, Panyam J, Hoye TR. Silicate esters of paclitaxel and docetaxel: synthesis, hydrophobicity, hydrolytic stability, cytotoxicity, and prodrug potential. J. Med. Chem. 57(6), 2368–2379 (2014).
  Medline CASGoogle Scholar
• 86. Han J, Michel AR, Lee HS et al. Nanoparticles containing high loads of paclitaxel-silicate prodrugs: formulation, drug release, and anticancer efficacy. Mol. Pharm. 12(12), 4329–4235 (2015).
  Medline CASGoogle Scholar
• 87. Giarra S, Serri C, Russo L et al. Spontaneous arrangement of a tumor targeting hyaluronic acid shell on irinotecan loaded PLGA nanoparticles. Carbohydr. Polym. 140, 400–407 (2016).
  Medline CASGoogle Scholar
• 88. Poudel BK, Gupta B, Ramasamy T et al. Development of polymeric irinotecan nanoparticles using a novel lactone preservation strategy. Int. J. Pharm. 512(1), 75–86 (2016).
  Medline CASGoogle Scholar
• 89. Holmkvist AD, Friberg A, Nilsson UJ, Schouenborg J. Hydrophobic ion pairing of a minocycline/Ca(2+)/AOT complex for preparation of drug-loaded PLGA nanoparticles with improved sustained release. Int. J. Pharm. 499(1–2), 351–357 (2016).
  Medline CASGoogle Scholar
• 90. Wang H, Agarwal P, Zhao S et al. Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials 72, 74–89 (2015).
  Medline CASGoogle Scholar
• 91. Gao Z, Li Z, Yan J, Wang P. Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy. Drug Des. Devel. Ther. 11, 2595–2604 (2017).
  Medline CASGoogle Scholar
• 92. Ramasamy T, Kim J, Choi HG, Yong CS, Kim JO. Novel dual drug-loaded block ionomer complex micelles for enhancing the efficacy of chemotherapy treatments. J. Biomed. Nanotechnol. 10(7), 1304–1312 (2014).
  Medline CASGoogle Scholar
• 93. Oh KT, Bronich TK, Bromberg L, Hatton TA, Kabanov AV. Block ionomer complexes as prospective nanocontainers for drug delivery. J. Control. Rel. 115(1), 9–17 (2006).
  Medline CASGoogle Scholar
• 94. Ramasamy T, Choi JY, Cho HJ et al. Polypeptide-based micelles for delivery of irinotecan: physicochemical and in vivo characterization. Pharm. Res. 32(6), 1947–1956 (2015).
  Medline CASGoogle Scholar
• 95. Nguyen F, Alferiev I, Guan P et al. Enhanced intratumoral delivery of SN38 as a tocopherol oxyacetate prodrug using nanoparticles in a neuroblastoma xenograft model. Clin. Cancer Res. 24(11), 2585–2593 (2018).
  Medline CASGoogle Scholar
• 96. Watermann A, Brieger J. Mesoporous silica nanoparticles as drug delivery vehicles in cancer. Nanomaterials 7(7), E189 (2017). • Review for mesoporous silica nanoparticles as the drug delivery systems.
  MedlineGoogle Scholar
• 97. Manzano M, Vallet-Regí M. Mesoporous silica nanoparticles in nanomedicine applications. J. Mater. Sci. Mater. Med. 29(5), 65 (2018).
  MedlineGoogle Scholar
• 98. Kettiger H, Sen Karaman D, Schiesser L, Rosenholm JM, Huwyler J. Comparative safety evaluation of silica-based particles. Toxicol. In Vitro 30(1 Pt B), 355–363 (2015).
  Medline CASGoogle Scholar
• 99. Ravera M, Perin E, Gabano E et al. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs. J. Inorg. Biochem. 151, 132–42 (2015).
  Medline CASGoogle Scholar
• 100. Ravera M, Gabano E, Zanellato I, Perin E, Arrais A, Osella D. Functionalized nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs. Dalton Trans. 45(43), 17233–17240 (2016).
  Medline CASGoogle Scholar
• 101. Du X, Xiong L, Dai S, Qiao SZ. γ-PGA-coated mesoporous silica nanoparticles with covalently attached prodrugs for enhanced cellular uptake and intracellular GSH-responsive release. Adv. Healthc. Mater. 4(5), 771–781 (2015).
  Medline CASGoogle Scholar
• 102. Goess R, Friess H. A look at the progress of treating pancreatic cancer over the past 20 years. Expert Rev. Anticancer Ther. 18(3), 295–304 (2018).
  Medline CASGoogle Scholar
• 103. Moysan E, Bastiat G, Benoit JP. Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications. Mol. Pharm. 10(2), 430–444 (2013).
  Medline CASGoogle Scholar
• 104. Malfanti A, Miletto I, Bottinelli E et al. Delivery of gemcitabine prodrugs employing mesoporous silica nanoparticles. Molecules 21(4), 522 (2016).
  MedlineGoogle Scholar
• 105. Yuan A, Wu J, Tang X, Zhao L, Xu F, Hu Y. Application of near-infrared dyes for tumor imaging, photothermal, and photodynamic therapies. J. Pharm. Sci. 102(1), 6–28 (2013).
  Medline CASGoogle Scholar
• 106. Li T, Shen X, Xie X et al. Irinotecan/IR-820 coloaded nanocomposite as a cooperative nanoplatform for combinational therapy of tumor. Nanomedicine 13(6), 595–603 (2018).
  Medline CASGoogle Scholar
• 107. Liu X, Situ A, Kang Y et al. Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer. ACS Nano 10(2), 2702–2715 (2016).
  Medline CASGoogle Scholar
• 108. Grinberg S, Linder C, Heldman E. Progress in lipid-based nanoparticles for cancer therapy. Crit. Rev. Oncog. 19(3–4), 247–260 (2014).
  MedlineGoogle Scholar
• 109. Pignatello R, Acquaviva R, Campisi A, Raciti G, Musumeci T, Puglisi G. Effects of liposomal encapsulation on the antioxidant activity of lipophilic prodrugs of idebenone. J. Liposome Res. 21(1), 46–54 (2011).
  Medline CASGoogle Scholar
• 110. Du R, Zhong T, Zhang WQ et al. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma. Int. J. Nanomed. 9, 3091–3105 (2014).
  Medline CASGoogle Scholar
• 111. Xiong H, Yu Q, Gong Y et al. Yes-associated protein (YAP) promotes tumorigenesis in melanoma cells through stimulation of low-density lipoprotein receptor-related protein 1 (LRP1). Sci. Rep. 7(1), 15528 (2017).
  MedlineGoogle Scholar
• 112. Ramsay EC, Anantha M, Zastre J et al. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin. Cancer Res. 14(4), 1208–1217 (2008).
  Medline CASGoogle Scholar
• 113. Verreault M, Strutt D, Masin D et al. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C^®), doxorubicin (Caelyx^®) or vincristine. BMC Cancer 11, 124 (2011).
  Medline CASGoogle Scholar
• 114. Waterhouse DN, Sutherland BW, Santos ND et al. Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities. Invest. New Drugs 32(6), 1071–1082 (2014). • An example of Irinophore C application.
  Medline CASGoogle Scholar
• 115. Chen PY, Ozawa T, Drummond DC et al. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro-Oncol. 15(2), 189–197 (2013).
  Medline CASGoogle Scholar
• 116. Klouda L. Thermoresponsive hydrogels in biomedical applications: a seven-year update. Eur. J. Pharm. Biopharm. 97(Pt B), 338–349 (2015).
  Medline CASGoogle Scholar
• 117. Din FU, Choi JY, Kim DW et al. Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration. Drug Deliv. 24(1), 502–510 (2017).
  MedlineGoogle Scholar
• 118. Attama AA. SLN, NLC, LDC: state of the art in drug and active delivery. Recent Pat. Drug Deliv. Formul. 5(3), 178–187 (2011).
  Medline CASGoogle Scholar
• 119. Sun B, Luo C, Li L et al. Core-matched encapsulation of an oleate prodrug into nanostructured lipid carriers with high drug loading capability to facilitate the oral delivery of docetaxel. Colloids Surf. B Biointerfaces 143, 47–55 (2016).
  Medline CASGoogle Scholar
• 120. Mody VV, Siwale R, Singh A, Mody HR. Introduction to metallic nanoparticles. J. Pharm. Bioallied. Sci. 2(4), 282–289 (2010). • Review for metallic nanoparticles used for biomedical application.
  Medline CASGoogle Scholar
• 121. Li K, Nejadnik H, Daldrup-Link HE. Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics. Drug Discov. Today 22(9), 1421–1429 (2017).
  Medline CASGoogle Scholar
• 122. Yu C, Ding B, Zhang X et al. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo. Biomaterials 155, 112–123 (2018).
  Medline CASGoogle Scholar
• 123. Engel JB, Tinneberg HR, Rick FG, Berkes E, Schally AV. Targeting of peptide cytotoxins to LHRH receptors for treatment of cancer. Curr. Drug Targets 17(5), 488–494 (2016).
  Medline CASGoogle Scholar
• 124. Lala MA, Ioannou PV. The reaction of allyl and benzylarsonic acids with thiols: mechanistic aspects and implications for dioxygen activation by trivalent arsenic compounds. J. Inorg. Biochem. 97(4), 331–339 (2003).
  Medline CASGoogle Scholar
• 125. Minehara H, Narita A, Naka K et al. Tumor cell-specific prodrugs using arsonic acid-presenting iron oxide nanoparticles with high sensitivity. Bioorg. Med. Chem. 20(15), 4675–4679 (2012).
  Medline CASGoogle Scholar
• 126. Mu Q, Jeon M, Hsiao MH et al. Stable and efficient Paclitaxel nanoparticles for targeted glioblastoma therapy. Adv. Healthc. Mater. 4(8), 1236–1245 (2015).
  Medline CASGoogle Scholar
• 127. Monteiro APF, Caminhas LD, Ardisson JD, Paniago R, Cortés ME, Sinisterra RD. Magnetic nanoparticles coated with cyclodextrins and citrate for irinotecan delivery. Carbohydr. Polym. 163, 1–9 (2017).
  Medline CASGoogle Scholar
• 128. Zhang XF, Liu ZG, Shen W, Gurunathan S. Silver nanoparticles: synthesis, characterization, properties, applications, and therapeutic approaches. Int. J. Mol. Sci. 17(9), E1534 (2016).
  MedlineGoogle Scholar
• 129. Qiu L, Li JW, Hong CY, Pan CY. Silver nanoparticles covered with pH-sensitive camptothecin-loaded polymer prodrugs: switchable fluorescence ‘off’ or ‘on’ and drug delivery dynamics in living cells. ACS Appl. Mater. Interfaces 9(46), 40887–40897 (2017).
  Medline CASGoogle Scholar
• 130. Maiyo F, Singh M. Selenium nanoparticles: potential in cancer gene and drug delivery. Nanomedicine 12(9), 1075–1089 (2017).
  Medline CASGoogle Scholar
• 131. Gao F, Yuan Q, Gao L et al. Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles. Biomaterials 35(31), 8854–8866 (2014).
  Medline CASGoogle Scholar